Jeff Behrens

Jeff Behrens is currently Senior Director, Business Development and Operations at Edimer Pharmaceuticals which is focusing on developing a drug to treat a rare genetic disease – XLHED. Edimer is funded by Third Rock Ventures in Boston and VI Partners in Switzerland. Jeff has broad responsibilities with manufacturing, finance, operations, and business development/alliance/partnering.

Formerly, Jeff was Director, Strategic Alliances at Alnylam and Co-founder and Head of Business Operations of "BI3" - The Biogen Idec Innovation Incubator - where he launched 2 companies funded by Biogen Idec – Escoublac and Provasculon working on diabetes and cardiovascular indications .

In 2003 Jeff sold his health-care IT company, The Telluride Group, to mindSHIFT Technologies, a Fidelity-funded rollup. Telluride was an angel financed manager services provider (MSP). Jeff is currently an Entrepreneur In Residence at the MIT Sloan Entrepreneurship Center, a member Mass Medical Angels, and a mentor with MIT’s Venture Mentoring Service.

Jeff volunteers with several community organizations including the Harvard Alumni Association and sits on the boards of Tufts Medical Center and The Speakeasy Stage Company in Boston. Jeff has a Lecturer appointment and currently teaches in the HST PhD program at MIT and Harvard Medical School. Jeff has an MS from the Harvard/MIT Division of Health Sciences and Technology (HST), an MBA from MIT Sloan, and graduated from Harvard College. He lives in Newton, MA.